AstraZeneca and Incyte Corporation announce collaboration on INCB39110 in non-small cell lung cancer

AstraZeneca and Incyte Corporation announced a new collaboration to evaluate the efficacy and safety of Incyte�s Janus-associated kinase (JAK) 1 inhibitor, INCB39110, in combination with AstraZeneca�s next generation epidermal growth factor receptor (EGFR) inhibitor, Tagrisso (osimertinib). The combination will be assessed as a second line treatment for patients with EGFR mutation-positive non-small cell lung cancer (NSCLC), who have been treated with a first generation EGFR tyrosine kinase inhibitor (TKI) and subsequently developed the T790M resistance mutation.